The U.S. Food and Drug Administration granted accelerated approval on August 6 to Tudriqev, a genetically modified oncolytic viral therapy, in combination with nivolumab for adults with unresectable advanced cutaneous melanoma that has progressed after treatment with a PD-1 blocking antibody-based regimen.